Encephalomyelitis Market Report 2026

Encephalomyelitis Market Overview

• Encephalomyelitis market size has reached to $22.58 billion in 2025 • Expected to grow to $30.84 billion in 2030 at a compound annual growth rate (CAGR) of 6.4% • Growth Driver: Impact Of Growing Autoimmune Diseases On Market Growth • Market Trend: Advancements In Monoclonal Antibody Therapies For Encephalomyelitis Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Encephalomyelitis Market?

Encephalomyelitis refers to the inflammation affecting both the brain and spinal cord, resulting from infections, immune system dysfunction, or other medical conditions. This condition causes neurological issues, including muscle weakness, paralysis, and cognitive disturbances. The main types in the encephalomyelitis are equine encephalomyelitis, associated encephalomyelitis, anti-myelin oligodendrocyte glycoprotein antibody (antimog), encephalomyelitis disseminata, acute disseminated encephalomyelitis, AIDS-related encephalomyelitis, and others. Equine encephalomyelitis is a viral disease that affects horses, caused by the eastern, western, or venezuelan equine encephalitis viruses, resulting in brain and spinal cord inflammation. The various treatments include surgery, plasmapheresis, drug treatment, and others and is utilized by various end users such as clinics, hospitals, and others.

What Is The Encephalomyelitis Market Growth Forecast?

The encephalomyelitis market size is expected to see strong growth in the next few years. It will grow to $30.84 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to advanced immunotherapies, early diagnosis programs, neurological rehabilitation demand, research into rare neurological diseases, healthcare infrastructure growth. Major trends in the forecast period include growing awareness of neuroinflammatory disorders, increased diagnosis of autoimmune neurological conditions, rising demand for long-term neurological care, expansion of immunomodulatory treatment approaches, focus on early neurological intervention.

Global Encephalomyelitis Market Segmentation

1) By Type: Equine Encephalomyelitis, Associated Encephalomyelitis, Anti-Myelin Oligodendrocyte Glycoprotein Antibody (AntiMOG), Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis, Other Types 2) By Treatment: Surgery, Plasmapheresis, Drug Treatment, Other Treatments 3) By End-users: Clinics, Hospitals, Other End-Users Subsegments: 1) By Equine Encephalomyelitis: Eastern Equine Encephalomyelitis, Western Equine Encephalomyelitis, Venezuelan Equine Encephalomyelitis 2) By Associated Encephalomyelitis: Post-Infectious Encephalomyelitis, Paraneoplastic Encephalomyelitis, Vaccine-Associated Encephalomyelitis 3) By Anti-Myelin Oligodendrocyte Glycoprotein Antibody (AntiMOG): MOG Antibody-Positive Encephalomyelitis, MOG Antibody-Associated Neuromyelitis Optica Spectrum Disorder 4) By Encephalomyelitis Disseminata: Multiple Sclerosis-Related Encephalomyelitis, Relapsing-Remitting Encephalomyelitis Disseminata, Progressive Encephalomyelitis Disseminata 5) By Acute Disseminated Encephalomyelitis: Post-Viral Acute Disseminated Encephalomyelitis, Post-Vaccination Acute Disseminated Encephalomyelitis 6) By AIDS-Related Encephalomyelitis: HIV-Associated Encephalomyelitis, Opportunistic Infection-Related Encephalomyelitis, Other AIDS-Related Encephalomyelitis 7) By Other Types: Idiopathic Encephalomyelitis, Autoimmune Encephalomyelitis, Rare Genetic Encephalomyelitis Variants

What Is The Driver Of The Encephalomyelitis Market?

The growing prevalence of autoimmune diseases is expected to propel the growth of the encephalomyelitis market going forward. Autoimmune diseases refer to conditions in which the body's immune system mistakenly attacks its own healthy cells and tissues. The rise in autoimmune diseases is attributed to factors such as genetic predisposition, environmental triggers, infections, and changes in lifestyle, including diet and exposure to chemicals. Encephalomyelitis treatment supports autoimmune disease patients by reducing inflammation, managing immune system dysfunction, alleviating neurological symptoms, and preventing disease progression, ultimately improving their overall quality of life and functional well-being. For instance, in February 2024 according to the Arthritis Australia is a Australia-based non-profit organization In 2025, an estimated 212,136 males and 362,137 females are projected to have rheumatoid arthritis (RA), with the numbers expected to rise by 2040 to approximately 280,040 males and 479,828 females. Therefore, the growing prevalence of autoimmune diseases is driving the growth of the encephalomyelitis industry.

Key Players In The Global Encephalomyelitis Market

Major companies operating in the encephalomyelitis market are Merck & Co. Inc., Sanofi S.A., F. Hoffmann-La Roche Ltd., HiFiBiO Therapeutics, Zoetis Services LLC, Chugai Pharmaceutical Co. Ltd., IDEXX, Abcam Limited., EUROIMMUN Medizinische Labordiagnostika AG, Eurogentec S.A., Boehringer Ingelheim International GmbH, Creative Diagnostics, Atlas Antibodies, AnaSpec, VMRD Inc., Antibodies Incorporated, Fresenius Kabi, Hemispherx Biopharma Inc., BioStoneah, YouSeq Ltd.

Global Encephalomyelitis Market Trends and Insights

Major companies operating in the encephalomyelitis market are focusing on developing advanced monoclonal antibody, to enhance treatment efficacy and develop targeted therapies for managing encephalomyelitis. Monoclonal antibody is an artificially created protein that attaches to specific antigens to aid the immune response against diseases. For instance, in March 2023, Chugai Pharmaceutical Co. Ltd, a Japan-based pharmaceutical company, announced that its humanized anti-IL-6 receptor monoclonal antibody, Enspryng has received forerunner designation from the Ministry of Health, Labor and Welfare (MHLW) for its anticipated use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and autoimmune encephalitis (AIE). This designation recognizes Enspryng’s potential as an innovative treatment, expediting its development and regulatory review to address the unmet medical needs of patients with these neurological conditions.

What Are Latest Mergers And Acquisitions In The Encephalomyelitis Market?

In January 2024, Zuellig Pharma Holdings Ltd., a Singapore-based hospital and healthcare company, partnered with Substipharm Biologics. The partnership improves IMOJEV Japanese encephalitis vaccine availability across nine Asian markets, leveraging Zuellig Pharma's marketing, distribution, and ZP Therapeutics' expertise to enhance vaccine access. Substipharm Biologics is a France-based pharmaceutical company develops various vaccines including encephalitis and encephalomyelitis vaccine.

Regional Outlook

North America was the largest region in the encephalomyelitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Encephalomyelitis Market?

The encephalomyelitis market consists of revenues earned by entities by providing services such as chest X-rays and CT scans, rapid diagnostic tests, sputum cultures, and blood cultures. The market value includes the value of related goods sold by the service provider or included within the service offering. The encephalomyelitis market also includes sales of antiviral therapy, and corticosteroids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Encephalomyelitis Market Report 2026?

The encephalomyelitis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the encephalomyelitis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.